retatrutide and blood clots GLP-1 RA's Increase Clot Risks Retatrutide Contraindications: Risks and Considerations

It is not FDA-approved for human use, which affects its legal availability and can impact pricing due to limited sources

However, another study found no significant correlation between endogenous GLP-1 levels and anticipatory activation for food cues (Perakakis et al., 2021)

Certain peptides

Patient characteristics associated with treatment discontinuation were similar for GLP-1 receptor agonists and SGLT2 inhibitors, although the association between higher BMI and a lower likelihood of treatment discontinuation was stronger for GLP-1 receptor agonists

References Messerli, F

Los agonistas del receptor GLP-1 (pptido similar al glucagn tipo 1), como semaglutida (Ozempic, Wegovy) y tirzepatida (Mounjaro, Zepbound, un agonista dual GIP/GLP-1), han transformado el manejo de la diabetes tipo 2 y la obesidad